Alleged compliance failures at Omnicare lead to healthcare fraud lawsuit
By 
Jaclyn Jaeger2019-12-19T16:25:00
A series of alleged compliance failures at pharmaceutical services provider Omnicare has resulted in the Department of Justice intervening in yet another civil healthcare fraud lawsuit against the company.
Related articles
-
ArticleMost-trafficked content tells story of the compliance officer
Changes in the interests of our audience over the last several years help us to understand how much compliance officers must evolve in their jobs to meet the demands of a given time.
-
Blog
Omnicare to pay $28M to settle kickback allegations
Omnicare this week agreed to pay $28.1 million to resolve allegations that it solicited and received millions of dollars in kickbacks from drug maker Abbott Laboratories, the Justice Department announced. Jaclyn Jaeger has more.
-
Blog
Justice Department Intervenes in Whistleblower Suits Against Omnicare
The Justice Department recently intervened in two consolidated whistleblower lawsuits against drug company Omnicare over allegations that it solicited and received millions of dollars in kickbacks from drug maker Abbott Laboratories. “Although the U.S. Attorney’s Office for the Western District of Virginia is small, we will not waver in our ...
More from Regulatory Enforcement
-
ArticleLarge wound care practice pays $45M, agrees to monitoring
One of the largest wound care practices in the nation and its founder have agreed to pay $45 million and be subjected to third-party monitoring, to settle allegations that the business intentionally overbilled Medicare by priming its electronic medical records system to do so.
-
News BriefSEC dismisses SolarWinds case tied to 2020 cyberattack
The dismissal of charges against SolarWinds for alleged cybersecurity lapses related to a 2020 Russian cyberattack in 2020 are the latest in a continuing pattern of leniency for corporations by the Trump administration.
-
PremiumPart Two: FCPA cases closed by DOJ, SEC since January
Since the start of the Trump Administration, the Department of Justice has been winding down a number of Foreign Corrupt Practices Act investigations with little public attention. This second article further explores how and why these FCPA matters have been closed.